Progression of cutaneous melanoma: implications for treatment
- PMID: 22892755
- PMCID: PMC4311146
- DOI: 10.1007/s10585-012-9521-1
Progression of cutaneous melanoma: implications for treatment
Erratum in
- Clin Exp Metastasis. 2012 Oct;29(7):797-9
Abstract
The survival rates of melanoma, like any type of cancer, become worse with advancing stage. Spectrum theory is most consistent with the progression of melanoma from the primary site to the in-transit locations, regional or sentinel lymph nodes and beyond to the distant sites. Therefore, early diagnosis and surgical treatment before its spread is the most effective treatment. Recently, new approaches have revolutionized the diagnosis and treatment of melanoma. Genomic profiling and sequencing will form the basis for molecular taxonomy for more accurate subgrouping of melanoma patients in the future. New insights of molecular mechanisms of metastasis are summarized in this review article. Sentinel lymph node biopsy has become a standard of care for staging primary melanoma without the need for a more morbid complete regional lymph node dissection. With recent developments in molecular biology and genomics, novel molecular targeted therapy is being developed through clinical trials.
Figures
Similar articles
-
Cutaneous melanoma: a model to study cancer metastasis.J Surg Oncol. 2011 May 1;103(6):538-49. doi: 10.1002/jso.21816. J Surg Oncol. 2011. PMID: 21480247 Review.
-
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15. Recent Results Cancer Res. 2000. PMID: 10857171 Review.
-
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.Plast Reconstr Surg. 2003 Aug;112(2):486-97. doi: 10.1097/01.PRS.0000070989.23469.1F. Plast Reconstr Surg. 2003. PMID: 12900606
-
The impact of surgery on the course of melanoma.Recent Results Cancer Res. 2002;160:151-7. doi: 10.1007/978-3-642-59410-6_18. Recent Results Cancer Res. 2002. PMID: 12079209
-
Lymphatic mapping and sentinel lymph node biopsy in the management of primary cutaneous melanoma: report of a single-centre experience.Tumori. 2006 Mar-Apr;92(2):113-7. doi: 10.1177/030089160609200205. Tumori. 2006. PMID: 16724689
Cited by
-
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.J Transl Med. 2013 Aug 29;11:202. doi: 10.1186/1479-5876-11-202. J Transl Med. 2013. PMID: 23987572 Free PMC article.
-
Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.World J Clin Oncol. 2016 Apr 10;7(2):174-88. doi: 10.5306/wjco.v7.i2.174. World J Clin Oncol. 2016. PMID: 27081640 Free PMC article. Review.
-
Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma.Biologics. 2016 Jul 5;10:89-98. doi: 10.2147/BTT.S109643. eCollection 2016. Biologics. 2016. PMID: 27462139 Free PMC article.
-
3D Bioprinting: An Enabling Technology to Understand Melanoma.Cancers (Basel). 2022 Jul 20;14(14):3535. doi: 10.3390/cancers14143535. Cancers (Basel). 2022. PMID: 35884596 Free PMC article. Review.
-
Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015. Am J Cancer Res. 2015. PMID: 26101714 Free PMC article.
References
-
- Murphy MJ. Diagnostic and prognostic biomarkers and therapeutic targets in melanoma. Springer; New York: 2012.
-
- Becker D, Mihm MC, Hewitt SM, et al. Markers and tissue resources for melanoma: meeting report. Cancer Res. 2006;66:10652–10657. - PubMed
-
- Beecher C. The human metabolome. In: Harrigan G, Goodacre R, editors. Metabolic profilings: its role in biomarker discovery and gene function analysis. Kluwer Academic Publishers; Boston: 2003. pp. 311–319.
-
- Flaherty KT. BRAF inhibitors and melanoma. Cancer J. 2011;17:505–511. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical